Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Sunday, Bristol Myers Squibb's Checkmate-067 Trial 10-Year Follow-Up Showed Continued Durable Long-Term Survival Benefit With Opdivo + Yervoy In Advanced Melanoma

Author: Benzinga Newsdesk | September 16, 2024 02:58am
  • These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference
  • At ten years, more than 40% (43%) of patients treated with Opdivo plus Yervoy were alive; a decade ago, this patient population faced a survival rate of around 25% after only one year
  • Data to be presented today as a mini oral and simultaneously published in TheNew England Journal of Medicine

Posted In: BMY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist